Endo will remove its extended-release opioid pain medication Opana ER from the market. The drug had sales of nearly $159 million last year.
A Mount Laurel nursing home whose Medicare agreement was canceled June 16 will remain open while a new owner seeks certification.
Virtua's board picked an executive from Baltimore to head South Jersey's largest health system.
Private insurance coverage could help rehabilitate the reputation of methadone maintenance.
The Republican governor, who has sought to tap the reserves of the state's largest insurer to pay for drug treatment for the poor and uninsured, drew attention to fines levied by the state against Horizon.
The Kennett Square company said last summer that it had reached a preliminary agreement to settle the allegations of improper billing.
Eric M. Green started his career as a chemist, but it wasn't long before he was promoted into management positions.
The Food and Drug Administration asked Endo Pharmaceuticals in Malvern to remove its drug Opana ER because its risks of abuse outweighed the benefits.
When West Pharmaceutical Services chief executive Eric Green needs a little stress relief, he pays a visit to his company's laboratories. In a white jacket and safety glasses, the former chemist gets to trade talk of share prices and corporate strategy for the fine points in developing the latest in...
Teva Pharmaceutical Industries said its experimental drug cut chronic migraines in a Phase 3 patient study.
Iroko Pharmaceutical's headcount is down to 19 at the Navy Yard, as the drug maker faces pending generic competition for a prescription pain medicine.
Pennsylvania will receive $1.4 million in a national settlement that McNeil, a Johnson & Johnson company, distributed contaminated over-the-counter medications, including Tylenol.
Going beyond law enforcement, Pa. Attorney General Josh Shapiro lays out 10-point plan to improve substance-abuse treatment.
Spark Therapeutic’s treatment for rare inherited blindness, if approved by the FDA, could be the first gene therapy medicine for a genetic disease in the United States.
The new policy will make anyone on Medicaid who is infected with hepatitis C eligible for treatment. An advisory panel recommended the change one year ago. It will be costly for the state.
